networkpharma limited
networkpharma limited Company Information
Company Number
04392836
Next Accounts
Dec 2025
Industry
Other information technology and computer service activities
Directors
Shareholders
peter llewellyn
Group Structure
View All
Contact
Registered Address
6-7 citibase, new barclay house, 234 botley road, oxford, OX2 0HP
Website
www.networkpharma.comnetworkpharma limited Estimated Valuation
Pomanda estimates the enterprise value of NETWORKPHARMA LIMITED at £271.4k based on a Turnover of £528.9k and 0.51x industry multiple (adjusted for size and gross margin).
networkpharma limited Estimated Valuation
Pomanda estimates the enterprise value of NETWORKPHARMA LIMITED at £147.4k based on an EBITDA of £40.9k and a 3.61x industry multiple (adjusted for size and gross margin).
networkpharma limited Estimated Valuation
Pomanda estimates the enterprise value of NETWORKPHARMA LIMITED at £451.4k based on Net Assets of £202.2k and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Networkpharma Limited Overview
Networkpharma Limited is a live company located in oxford, OX2 0HP with a Companies House number of 04392836. It operates in the other information technology service activities sector, SIC Code 62090. Founded in March 2002, it's largest shareholder is peter llewellyn with a 100% stake. Networkpharma Limited is a mature, small sized company, Pomanda has estimated its turnover at £528.9k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Networkpharma Limited Health Check
Pomanda's financial health check has awarded Networkpharma Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
3 Strong
3 Regular
4 Weak
Size
annual sales of £528.9k, make it smaller than the average company (£6.9m)
- Networkpharma Limited
£6.9m - Industry AVG
Growth
3 year (CAGR) sales growth of 9%, show it is growing at a similar rate (8.8%)
- Networkpharma Limited
8.8% - Industry AVG
Production
with a gross margin of 24.9%, this company has a higher cost of product (48%)
- Networkpharma Limited
48% - Industry AVG
Profitability
an operating margin of 7.7% make it more profitable than the average company (3.8%)
- Networkpharma Limited
3.8% - Industry AVG
Employees
with 1 employees, this is below the industry average (41)
1 - Networkpharma Limited
41 - Industry AVG
Pay Structure
on an average salary of £70.9k, the company has an equivalent pay structure (£70.9k)
- Networkpharma Limited
£70.9k - Industry AVG
Efficiency
resulting in sales per employee of £528.9k, this is more efficient (£170.1k)
- Networkpharma Limited
£170.1k - Industry AVG
Debtor Days
it gets paid by customers after 162 days, this is later than average (53 days)
- Networkpharma Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 35 days, this is close to average (36 days)
- Networkpharma Limited
36 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Networkpharma Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Networkpharma Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 16.2%, this is a lower level of debt than the average (63.3%)
16.2% - Networkpharma Limited
63.3% - Industry AVG
NETWORKPHARMA LIMITED financials
Networkpharma Limited's latest turnover from March 2024 is estimated at £528.9 thousand and the company has net assets of £202.2 thousand. According to their latest financial statements, Networkpharma Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | |||||||||||||||
| Tax | |||||||||||||||
| Profit After Tax | |||||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | |||||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 5,556 | 2,730 | 25,702 | 88 | 336 | 8,610 | 12,473 | 18,301 | 121 | 1 | 206 | 1,143 | 2,446 | 2,142 | 726 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 297 | 369 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 5,556 | 2,730 | 25,702 | 88 | 336 | 8,610 | 12,473 | 18,301 | 121 | 1 | 206 | 1,143 | 2,446 | 2,439 | 1,095 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 235,653 | 314,972 | 265,198 | 180,612 | 118,765 | 95,481 | 168,287 | 159,387 | 49,915 | 45,532 | 34,505 | 45,382 | 8,740 | 19,058 | 17,878 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84,270 | 84,625 | 59,838 | 52,245 | 42,946 | 38,760 | 32,692 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 235,653 | 314,972 | 265,198 | 180,612 | 118,765 | 95,481 | 168,287 | 159,387 | 134,185 | 130,157 | 94,343 | 97,627 | 51,686 | 57,818 | 50,570 |
| total assets | 241,209 | 317,702 | 290,900 | 180,700 | 119,101 | 104,091 | 180,760 | 177,688 | 134,306 | 130,158 | 94,549 | 98,770 | 54,132 | 60,257 | 51,665 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 38,970 | 146,108 | 128,136 | 112,064 | 74,806 | 18,082 | 21,812 | 18,764 | 61,289 | 75,069 | 59,370 | 78,795 | 40,403 | 47,241 | 32,049 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 435 | 1,535 | 799 | 0 | 0 | 0 | 15,310 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current liabilities | 38,970 | 146,108 | 128,136 | 112,064 | 74,806 | 18,082 | 21,812 | 18,764 | 61,724 | 76,604 | 60,169 | 78,795 | 40,403 | 47,241 | 47,359 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 52,091 | 58,849 | 46,540 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 6,025 | 7,745 | 9,465 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 58,116 | 66,594 | 56,005 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 38,970 | 146,108 | 128,136 | 112,064 | 74,806 | 76,198 | 88,406 | 74,769 | 61,724 | 76,604 | 60,169 | 78,795 | 40,403 | 47,241 | 47,359 |
| net assets | 202,239 | 171,594 | 162,764 | 68,636 | 44,295 | 27,893 | 92,354 | 102,919 | 72,582 | 53,554 | 34,380 | 19,975 | 13,729 | 13,016 | 4,306 |
| total shareholders funds | 202,239 | 171,594 | 162,764 | 68,636 | 44,295 | 27,893 | 92,354 | 102,919 | 72,582 | 53,554 | 34,380 | 19,975 | 13,729 | 13,016 | 4,306 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 62 | 205 | 937 | 1,921 | 2,177 | 1,552 | 640 | ||||||||
| Amortisation | 0 | 0 | 0 | 0 | 0 | 72 | 72 | ||||||||
| Tax | |||||||||||||||
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -79,319 | 49,774 | 84,586 | 61,847 | 23,284 | -72,806 | 8,900 | 109,472 | 4,383 | 11,027 | -10,877 | 36,642 | -10,318 | 1,180 | 17,878 |
| Creditors | -107,138 | 17,972 | 16,072 | 37,258 | 56,724 | -3,730 | 3,048 | -42,525 | -13,780 | 15,699 | -19,425 | 38,392 | -6,838 | 15,192 | 32,049 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | -52,091 | -6,758 | 12,309 | 46,540 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -435 | -1,100 | 736 | 799 | 0 | 0 | -15,310 | 15,310 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | -6,025 | -1,720 | -1,720 | 9,465 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | |||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -84,270 | -355 | 24,787 | 7,593 | 9,299 | 4,186 | 6,068 | 32,692 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -84,270 | -355 | 24,787 | 7,593 | 9,299 | 4,186 | 6,068 | 32,692 |
networkpharma limited Credit Report and Business Information
Networkpharma Limited Competitor Analysis
Perform a competitor analysis for networkpharma limited by selecting its closest rivals, whether from the INFORMATION AND COMMUNICATION sector, other small companies, companies in OX2 area or any other competitors across 12 key performance metrics.
networkpharma limited Ownership
NETWORKPHARMA LIMITED group structure
Networkpharma Limited has no subsidiary companies.
Ultimate parent company
NETWORKPHARMA LIMITED
04392836
networkpharma limited directors
Networkpharma Limited currently has 1 director, Mr Peter Llewellyn serving since Mar 2002.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Peter Llewellyn | England | 63 years | Mar 2002 | - | Director |
P&L
March 2024turnover
528.9k
-23%
operating profit
40.9k
0%
gross margin
24.9%
-3.86%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
202.2k
+0.18%
total assets
241.2k
-0.24%
cash
0
0%
net assets
Total assets minus all liabilities
networkpharma limited company details
company number
04392836
Type
Private limited with Share Capital
industry
62090 - Other information technology and computer service activities
incorporation date
March 2002
age
22
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
MERCER LEWIN LTD
auditor
-
address
6-7 citibase, new barclay house, 234 botley road, oxford, OX2 0HP
Bank
-
Legal Advisor
-
networkpharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to networkpharma limited.
networkpharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
